Advertisement

Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin

  • Xiang Ji
  • Michelle McFarlane
  • Henry Liu
  • Annie Dupuis
  • Carol A. WestallEmail author
Original Research Article

Abstract

Purpose

The anti-epileptic drug vigabatrin is associated with reduction in light-adapted 30-Hz flicker electroretinogram (ERG) amplitude. Ophthalmological assessments, including ERGs, monitor retinal health during vigabatrin treatment. RETeval™ is a hand-held ERG device adapted for dilation-free ERG assessment. To evaluate the usefulness of RETeval™ for vigabatrin ERG assessment, we evaluated intra-visit reliability and clinical feasibility of RETeval™ ERG assessment in children under 3 years of age undergoing vigabatrin treatment.

Methods

In this prospective study, children underwent 30-Hz flicker ERG assessment with RETeval™ before routine vigabatrin monitoring including sedated-ERG using the Espion E2 Colour Dome. Intraclass correlation coefficient (ICC) statistics identified the degree of intra-visit reliability from two repeated measurements of the same participant within one testing session. The omega squared (ω2) statistic identified the level of association between RETeval™ and Espion light-adapted 30-Hz flicker responses.

Results

Nine children completed RETeval™ ERG testing. The intra-visit ICCs for the RETeval™ 30-Hz flicker amplitude (µV) were high: 0.81 (right eye) and 0.86 (left eye), while the implicit times (ms) were 0.79 (right eye) and 0.42 (left eye). The RETeval™ 30-Hz flicker amplitude was positively associated with the Espion 30-Hz flicker response (ω2 = 0.71). The Bland–Altman plot showed no bias in the mean difference of amplitudes between the two systems.

Conclusion

This is the first study to assess the utility of RETeval™ device in children under 3 years of age undergoing vigabatrin treatment. RETeval™ demonstrated high intra-visit reliability with responses consistent with the standard Espion ERG. RETeval™ may be beneficial for assessment of retinal toxicity in young children treated with vigabatrin.

Keywords

Electroretinography RETeval Hand-held electroretinography Vigabatrin Infantile spasms 

Notes

Acknowledgements

This work was supported by the Vision Science Research program at the University of Toronto (Xiang Ji), and the SickKids Ophthalmology Research Fund (Dr. Carol Westall). LKC Technologies, Inc. provided the RETeval™ device and some sensor strips electrodes used in this study.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

Statement of human rights

All research procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Statement on the welfare of animals

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all participants included in the study.

References

  1. 1.
    Riikonen R, Donner M (1979) Incidence and aetiology of infantile spasms from 1960 to 1976: a population study in Finland. Dev Med Child Neurol 21:333–343CrossRefPubMedGoogle Scholar
  2. 2.
    Sidenvall R, Eeg-Olofsson O (1995) Epidemiology of infantile spasms in Sweden. Epilepsia 36:572–574CrossRefPubMedGoogle Scholar
  3. 3.
    Rantala H, Putkonen T (1999) Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 40:286–289CrossRefPubMedGoogle Scholar
  4. 4.
    Wong M, Trevathan E (2001) Infantile spasms. Pediatr Neurol 24:89–98CrossRefPubMedGoogle Scholar
  5. 5.
    Chiron C, Dumas C, Jambaqué I et al (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26:389–395CrossRefPubMedGoogle Scholar
  6. 6.
    Jones K, Go C, Boyd J et al (2015) Vigabatrin as first-line treatment for infantile spasms not related to tuberous sclerosis complex. Pediatr Neurol 53:141–145CrossRefPubMedGoogle Scholar
  7. 7.
    Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180–181CrossRefGoogle Scholar
  8. 8.
    Lawden MC, Eke T, Degg C et al (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716–722CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Harding GF, Wild JM, Robertson KA et al (2000) Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Am J Ophthalmol 55:347–352Google Scholar
  10. 10.
    Good WV (2011) Measuring field loss in children administered vigabatrin: a problem in search of a solution. J AAPOS 15:411–412CrossRefPubMedGoogle Scholar
  11. 11.
    McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1–12CrossRefPubMedGoogle Scholar
  12. 12.
    Westall CA, Wright T, Cortese F et al (2014) Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study. Neurology 83:2262–2268CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sun L (2010) Early childhood general anaesthesia exposure and neurocognitive development. BJA Br J Anaesth 105:i61–i68CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang H, Du L, Du Z et al (2015) Association between childhood exposure to single general anesthesia and neurodevelopment: a systematic review and meta-analysis of cohort study. J Anesth 29:749–757CrossRefPubMedGoogle Scholar
  15. 15.
    Davidson AJ, Becke K, De Graaff J et al (2015) Anesthesia and the developing brain: a way forward for clinical research. Paediatr Anaesth 25:447–452CrossRefPubMedGoogle Scholar
  16. 16.
    Kato K, Kondo M, Sugimoto M et al (2015) Effect of pupil size on flicker ERGs recorded with RETeval system: new mydriasis-free full-field ERG system. Investig Ophthalmol Vis Sci 56:3684–3690CrossRefGoogle Scholar
  17. 17.
    Grace SF, Lam BL, Feuer WJ et al (2017) Nonsedated handheld electroretinogram as a screening test of retinal dysfunction in pediatric patients with nystagmus. J AAPOS 21:384–388CrossRefPubMedGoogle Scholar
  18. 18.
    Al-Otaibi H, Al-Otaibi MD, Khandekar R et al (2017) Validity, usefulness and cost of RET eval system for diabetic retinopathy screening. Transl Vis Sci Technol 6:3CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Miura G, Nakamura Y, Sato E, Yamamoto S (2016) Effects of cataracts on flicker electroretinograms recorded with RETevalTM system: new mydriasis-free ERG device. BMC Ophthalmol 16:22CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Asakawa K, Amino K, Iwase M et al (2017) New mydriasis-free electroretinogram recorded with skin electrodes in healthy subjects. Biomed Res Int 2017:1–7CrossRefGoogle Scholar
  21. 21.
    Liu H, Ji X, Dhaliwal S et al (2018) Evaluation of light- and dark-adapted ERGs using a mydriasis-free, portable system: clinical classifications and normative data. Doc Ophthalmol 137:169–181CrossRefPubMedGoogle Scholar
  22. 22.
    Davis CQ, Kraszewska O, Manning C (2017) Constant luminance (cd·s/m2) versus constant retinal illuminance (Td·s) stimulation in flicker ERGs. Doc Ophthalmol 134:75–87CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nakamura N, Fujinami K, Mizuno Y et al (2016) Evaluation of cone function by a handheld non-mydriatic flicker electroretinogram device. Clin Ophthalmol 10:1175–1185CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Xiang Ji
    • 1
    • 2
    • 3
  • Michelle McFarlane
    • 1
  • Henry Liu
    • 1
    • 4
  • Annie Dupuis
    • 5
  • Carol A. Westall
    • 1
    • 2
    • 3
    Email author
  1. 1.Ophthalmology and Vision SciencesThe Hospital for Sick ChildrenTorontoCanada
  2. 2.Institute of Medical ScienceUniversity of TorontoTorontoCanada
  3. 3.Ophthalmology and Vision SciencesUniversity of TorontoTorontoCanada
  4. 4.Faculty of MedicineUniversity of OttawaOttawaCanada
  5. 5.Clinical Research ServicesThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations